Get the Stockscreener App
10.96
0.05%
-0.005
Atara Biotherapeutics Inc stock is traded at $10.96, with a volume of 25,037.
It is down -0.05% in the last 24 hours and up +18.18% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$10.96
Open:
$11.03
24h Volume:
25,037
Relative Volume:
0.42
Market Cap:
$65.31M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.4253
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
-5.15%
1M Performance:
+18.18%
6M Performance:
+8.90%
1Y Performance:
+42.83%
1-Day Range:
$10.39
$11.66
1-Week Range:
$10.39
$11.84
52-Week Range:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
10.96 | 67.87M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Will Atara Biotherapeutics Inc. price bounce be sustainableOversold Reversal Picks with Buy Zone - Newser
Multi asset correlation models including Atara Biotherapeutics Inc.Free Real Time Stock Movement Analysis - Newser
What MACD signals say about Atara Biotherapeutics Inc.Real-Time Setup Summary with ROI Focus - Newser
Atara ATRA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Atara Biotherapeutics Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Biotech with Heart: Atara’s Path to Hope for MS & Cancer - Tomorrow's World Today
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner - sg.finance.yahoo.com
What is Atara Biotherapeutics Inc. company’s growth strategyUnlock powerful portfolio management tools - Jammu Links News
What is the risk reward ratio of investing in Atara Biotherapeutics Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
What are analysts’ price targets for Atara Biotherapeutics Inc. in the next 12 monthsStrong return on investment - Jammu Links News
What are the latest earnings results for Atara Biotherapeutics Inc.Rapid wealth multiplication - Jammu Links News
Does Atara Biotherapeutics Inc. stock perform well during market downturnsHigh-yield trading alerts - Jammu Links News
When is Atara Biotherapeutics Inc. stock expected to show significant growthUnlock powerful portfolio optimization tools - Jammu Links News
What analysts say about Atara Biotherapeutics Inc. stockDiscover stocks with explosive upside potential - Jammu Links News
Should I hold or sell Atara Biotherapeutics Inc. stock in 2025Maximize profits with strategic stock selection - Jammu Links News
What institutional investors are buying Atara Biotherapeutics Inc. stockTriple-digit wealth increases - Jammu Links News
What are Atara Biotherapeutics Inc. company’s key revenue driversGet real-time alerts on top-performing stocks - Jammu Links News
What drives Atara Biotherapeutics Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What is the dividend policy of Atara Biotherapeutics Inc. stockMaximize returns with disciplined trading approaches - Jammu Links News
What catalysts could drive Atara Biotherapeutics Inc. stock higher in 2025Discover high-growth stocks for your portfolio - Jammu Links News
Why is Atara Biotherapeutics Inc. stock attracting strong analyst attentionInvest smarter with data-backed trading alerts - Jammu Links News
Is it the right time to buy Atara Biotherapeutics Inc. stockConsistent high-yield stocks - Jammu Links News
What makes Atara Biotherapeutics Inc. stock price move sharplyNavigate market shifts with confidence - Jammu Links News
FDA Accepts Atara Biotherapeutics’ Resubmission of BLA for Tabelecleucel - CGTLive®
Atara Biotherapeutics Plunges 16.09% Post Reverse Split - AInvest
Atara Biotherapeutics Inc. Stock Lags Behind Sector BenchmarksHigh Accuracy Alerts for ROI Traders Detected - metal.it
Atara Biotherapeutics Inc. Recovery Potential Based on Technical ToolsValue Investing Picks With Stability Outlined - metal.it
Published on: 2025-07-29 09:26:28 - metal.it
Fibonacci Support Holding Strong in Atara Biotherapeutics Inc.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
Published on: 2025-07-28 23:04:32 - metal.it
Is Atara Biotherapeutics Inc. a growth stock or a value stockRapid return acceleration - Jammu Links News
Intrinsic Value of Atara Biotherapeutics Inc. Stock: Is It Undervalued or Overvalued Portfolio Positioning Strategy With Timing - metal.it
What are the technical indicators suggesting about Atara Biotherapeutics Inc.Build wealth faster with disciplined trading - Jammu Links News
How Atara Biotherapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Rocket Pharmaceuticals (RCKT) and Atara Biotherapeutics (ATRA) - The Globe and Mail
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):